Sunday, September 20, 2026

Aurora Cannabis Stock Takes A Hit: 13% Down At Opening

ViaNews Editorial Team

September 13, 2023

Aurora Cannabis Stock Takes A Hit: 13% Down At Opening

(VIANEWS) - Aurora Cannabis (NYSE: ACB) saw a steep 13.64% decrease to EUR0.83 at 10:02 EST Wednesday after five consecutive sessions of gains, yet broader market indices generally saw positive trends with the NYSE surging by 0.03% to EUR15,953.91 after three straight upticks.

About Aurora Cannabis

Aurora Cannabis Inc. is a Canadian company that specialises in producing and distributing cannabis-related products worldwide. Aurora operates across three segments - Canadian Cannabis, European Cannabis, and Plant Propagation. Aurora Cannabis produces medical and consumer cannabis products in Canada, distributes wholesale medical cannabis throughout Europe and international markets, propagate vegetables and ornamental plants across North America and provide propagated vegetables/ornamentals plants in North America. They also sell hemp-derived CBD products. Aurora Cannabis cultivates and sells various cannabis products, such as dried cannabis, oils, capsules, edibles, extracts and soft gels. Aurora offers recreational cannabis products and patient counseling services under various brands including Aurora Drift, San Rafael '71 Daily Special Whistler Being Greybeard. Based out of Leduc, Canada.

Technical Analysis

Aurora Cannabis (ACB) experienced an unprecedented spike in volume today, trading 2507,176 shares - which is 101.63% more than their average of 12,433,300 shares per day - suggesting there may be greater investor interest for their stock. Volatility analysis for this company found its intraday variation average for the past week, month, and quarter at 28.03%, 3.72% and 4.29%, respectively. The highest amplitude of average volatility over these time frames was 29.91% for week 2, month 1 and quarter 1 with 29.91% occurring over week 3. Aurora Cannabis stock has reached oversold status (=20), suggesting it may be undervalued and could experience a possible rebound soon. Given this information, investors may wish to monitor Aurora Cannabis stock for potential buying opportunities, particularly if its price continues to decrease. It should be remembered that stock prices can be affected by numerous factors and it is advised to conduct further research as well as consult a financial advisor prior to making any investment decisions.

Equity Analysis

Aurora Cannabis's trailing twelve months EPS value of EUR-10.54 indicates that they have not been profitable over the last twelve months. A negative EPS value could indicate significant expenses or losses which should raise concerns among potential investors. Aurora Cannabis may be investing heavily in growth initiatives that could pay dividends down the line, which should make potential investors cautious when using just EPS alone to evaluate their financial health. Prospective investors should also carefully consider other financial metrics, including revenue growth and cash flow as well as qualitative aspects like competitive position and regulatory environment before making investment decisions.

More news about Aurora Cannabis (ACB).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com